Compare Summit Therapeutics Inc (SMMT) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wynn Resorts, Limited — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Wynn Resorts, Limited trades at $90.51 (market cap $9.50B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Wynn Resorts, Limited pays a 1.08% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | WYNN | |
|---|---|---|
Market Cap | $13.79B | $9.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $133.34 |
52-Week Low | $12.43 | $90.23 |
Enterprise Value | $13.11B | $19.74B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, amid mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, though U.S. margins face pressure. Revenue reached $7.14B in 2025 with a net income margin of 4.58%, while debt remains elevated at $10.5B. Recent institutional buying includes Barrow Hanley's $321M investment, and analysts maintain a bullish consensus price target of $132.44.
Wynn's outlook is supported by Macau recovery and new project pipelines like Wynn Al Marjan, but high capital expenditure and debt load pose risks. The stock offers 44% upside to consensus target, though investors should monitor margin pressures and capex execution. Near-term support lies at $91, with resistance at $93.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
